1.

Introduction
Prostate cancer (PCa) is the most common malignancy in men and the second leading cause of death from cancer [1] . Almost 34% of men for whom radical treatment fails develop incurable metastatic disease [2] . Androgen deprivation is the mainstay of therapy for advanced PCa, but progression to a castration-resistant state invariably occurs after a median time of 18-24 mo [3] , while the median time from diagnosis of metastatic disease to death is 40.7 mo [4] . Evaluation of treatment responses in metastatic PCa remains challenging [5] . Bone represents the likeliest site of metastases, and almost 90% of patients have radiologic evidence of bone metastases [6, 7] , but this is non-evaluable according to Response Evaluation Criteria in Solid Tumors (RECIST) [8] . The consensus criteria of the Prostate Cancer Working Group (PCWG2) are used to report PCa outcomes in clinical trials. These rely on a composite measure of clinical, radiologic, and serologic (prostate-specific antigen [PSA] changes) outcomes to define response to treatment and progression [9] .
PSA continues to be widely used to monitor PCa [10, 11] . PCWG2 criteria recommend reporting PSA response as a continuous variable in the form of waterfall plots, although both 30% and 50% PSA declines are also commonly reported, usually at nadir and at 12 wk, and both are associated with improved survival [9] . A 30% PSA decline consistently has a stronger association with survival than a 50% PSA decline [12] [13] [14] . Similarly, PSA progression according to PCWG2 criteria is associated with shorter survival [15, 16] . Despite this, studies have not validated PSA decline as a surrogate of overall survival (OS), although a recently published pooled analysis of the COU-301 and COU-302 trials indicated that PSA kinetics, including PSA doubling time, satisfied the Prentice criteria for OS surrogacy [17] .
Defining the best time to assess response is also challenging. According to PCWG2 criteria, progression should not be determined during the first 12 wk because of late responses and flare reactions [9, 18, 19] . Insufficient data have therefore been reported regarding the clinical relevance of early PSA changes in mCRPC patients treated with abiraterone acetate (AA) [20] . We hypothesized that an early decline in PSA by 30% after 4 wk of treatment with AA is associated with improved OS and a 50% PSA decline at 12 wk, and that a PSA increase of 25% after 4 wk of treatment is associate with much poorer outcome and a high likelihood of a 50% PSA increase at 12 wk. If confirmed, these data could guide future studies on earlier treatment termination for insensitive disease.
2.
Patients and methods 
Study design and data collection
Endpoint definition
OS was defined as the time between treatment initiation and either the date of death or of last follow-up for surviving patients. PSA decline endpoints evaluated were consistent with published consensus guidelines [9] . PSA response at 12 wk was defined as either a 30% or a 50% decline in PSA relative to baseline, confirmed by a second reading at least 3 wk later. Early PSA response was defined as a 30% decline in PSA at 4 wk relative to baseline. Early and 12-wk PSA declines were also calculated as a continuous value, expressed as the percentage decline relative to baseline. PSA progression at 12 wk was defined as a 25% increase relative to baseline or, in cases with an initial PSA decline, relative to nadir, and a minimum PSA level of 2 ng/ml, confirmed by a second reading at least 3 wk later. Early PSA progression was defined as a 25% increase at 4 wk relative to baseline. 
Statistical analysis
PSA decline at 4 wk after AA treatment initiation
The median PSA change at 4 wk after treatment initiation was -21.2% (IQR -58% to +21.9%), and 126 patients (46%) achieved a 30% PSA decline at 4 wk. Early PSA decline was more frequent in the prechemotherapy cohort (52.1% vs 41.4%; p = 0.078). Overall, a 30% PSA decline at 4 wk was associated with substantially longer OS (25.8 vs 15.1 mo; HR 0.47, p < 0.001; Fig. 1A ) in univariable and multivariable Cox regression models (Table 2 and Supplementary  Table 1 ). Similar results were observed when analyzing the postchemotherapy and prechemotherapy cohorts separately (Table 2 , Fig. 1B,C) . Moreover, out of 126 patients with a 30% PSA decline at 4 wk, 106 (84.1%) achieved a confirmed 30% PSA decline and 90 (71.4%) a confirmed 50% PSA decline at 12 wk. Critically, among patients without a PSA decline at 4 wk, only 15 (10.1%) and nine (6.1%) had confirmed 30% and 50% PSA declines, respectively, at 12 wk. Moreover, the percentage PSA decline at 4 wk was significantly correlated with the percentage PSA change at 12 wk (r = 0.82; p < 0.001). Similar findings were observed for both the prechemotherapy and postchemotherapy cohorts (Table 3) . Furthermore, patients achieving a 30% PSA decline at 4 wk were 8.3 times more likely to have a 30% PSA decline at 12 wk, and (4) 7 (6) 4 (2.5) Pain, n (%) 0.000 
11.7 times more likely to have a 50% PSA decline at 12 wk. Early PSA response had sensitivity of 87.6% (95% CI 80.6-92.3%) and specificity of 86.9% (95% CI 80.7-91.4%) for detection of a 30% PSA response at 12 wk (Table 4) , and sensitivity of 90.9% (95% CI 83.6-95.1%) and specificity of 79.4% (95% CI 72.8-84.8%) for detection of a 50% PSA response at 12 wk. We defined the positive predictive value (PPV) as the probability of achieving a biochemical response at 12 wk for patients with an early PSA decline, and the negative predictive value (NPV) as the probability that patients with no decline at 4 wk will lack a 12-wk PSA response. We used the PSA data reported in the COU-301 (45.9%) and COU-302 (74.2%) trials for the prevalence of a 12-wk PSA response in the postchemotherapy and prechemotherapy cohorts, respectively. Early PSA response had PPV of 85.5% and 95.2%, and NPV of 94.8% and 63.1% for the postchemotherapy and prechemotherapy cohorts, respectively (Table 4 ).
3.3.
Rising PSA at 4 wk after AA treatment initiation
Overall, 102 patients (37.2%) experienced a 25% PSA rise after 4 wk of AA, of whom 36/117 were (30.8%) in the prechemotherapy group and 66/157 (42%) in the postchemotherapy group (nonsignificant trend, p = 0.056).
Patients with an early 25% PSA rise had significantly shorter OS than those without a 25% PSA rise (15.1 vs 23.8 mo; HR 1.7, 95% CI 1.3-2.4; p = 0.001) in both univariable and multivariable models ( Table 2, Supplementary Table 2) . A 25% PSA rise after 4 wk was associated with poorer outcome in both the prechemotherapy and postchemotherapy cohorts ( Table 2) .
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Fig. 1 -Kaplan-Meier curves for overall survival (OS) for a decrease in prostate-specific antigen of I30% at 4 wk as a dichotomous variable: (A) overall study population, (B) post-chemotherapy population, and (C) pre-chemotherapy population. CI = confidence interval; HR = hazard ratio calculated from Cox regression models.
Of 102 patients experiencing a 25% PSA rise at 4 wk, 49 (48%) experienced confirmed PCWG2 PSA progression (25% increase) at 12 wk; this early PSA rise was significantly associated with confirmed progression at 12 wk (p < 0.001). Patients experiencing a 25% PSA rise at 4 wk were 5.5 times more likely to have PCWG2 PSA progression at 12 wk (Table 5) . Of the patients with a 25% PSA rise at 4 wk, nine (8.8%) and four (3.9%) achieved confirmed 30% and 50% PSA responses, respectively, after 12 wk on AA. An early 25% PSA rise at 4 wk remained significantly associated with 12-wk PCWG2 PSA progression for the postchemotherapy and prechemotherapy cohorts (Table 5) . A 25% PSA rise at 4 wk had sensitivity of 76.6% (95% CI 64.9-85.3%) and specificity of 74.8% (95% CI 68.5-80.2%) for detection of confirmed progression at 12 wk (Table 4) . CI = confidence interval; RR = relative risk.
4.
Discussion
Better tools to assess treatment responses are needed to improve care for patients with advanced PCa, with patients currently receiving 12 wk of a new treatment before a switch decision is made owing to challenges in imaging bone disease [23] . Treatment switch decisions are frequently driven by alternative biomarkers (particularly PSA) and symptoms; this impacts progression-free survival measures, which may not always correlate with OS [24] . Post-treatment PSA changes correlate with prognosis but are not validated as a surrogate for survival [14] [15] [16] . Nonetheless, monthly PSA tests during treatment are commonly used to monitor responses, with a recent survey indicating that specialists frequently advise treatment switches before 12 wk on a novel treatment have elapsed [25] . Assessing PSA changes in the first 12 wk of treatment with novel androgen receptor (AR) signaling inhibitors is therefore of major practical relevance to routine patient care. We arguably describe the first correlation between PSA decline after 4 wk of AA + prednisolone treatment and outcome. We report that a PSA decline of 30% and PSA rise of 25% after only 4 wk of AA + prednisolone could identify patients who may or may not be benefitting from AA treatment, indicating a need for further validation studies to evaluate this critically important question. Overall, we report that patients with a PSA decline of 30% at 4 wk have substantially longer OS, with an 8.3-fold higher likelihood of a response at 12 wk. Of these patients, 78.5% and 90% in the prechemotherapy and postchemotherapy populations, respectively, had a 50% PSA decline at 12 wk.
Conversely, only 15.9% of patients with a 30% PSA decline at 4 wk did not meet the response criteria at 12 wk (Table 3) . However, concerns regarding misinterpretation of such early PSA changes have been raised because of late decreases in PSA reported for 20% of mCRPC patients treated with docetaxel [26] and cabazitaxel [19] . This phenomenon, described by some as PSA flare, may not be associated with a worse outcome [19] . Indeed, in a post hoc analysis of TAX-327 it was estimated that PSA flare (defined as any PSA rise not reaching the progression criterion or a rise that satisfied the progression criterion but with a later measurement that was <50% of the baseline value) occurred in 16.7% of patients [18] . However, drugs targeting AR signaling, such as abiraterone and enzalutamide, may have a very different relationship to early PSA decreases, since PSA is a excellent pharmacodynamic biomarker of AR signaling in the absence of aberrations of the PSA promoter or key regulators of PSA production and secretion [27] .
Conversely, we report that a 25% PSA rise at 4 wk was associated with a 5.5-fold higher likelihood of biochemical progression at 12 wk. Overall, only nine (3.2%) and four (1.5%) patients with a 25% PSA rise at 4 wk achieved 30% and 50% PSA decreases, respectively, at 12 wk; this early PSA increase was associated with worse prognosis in prechemotherapy (21.4 vs 43.6 mo; HR 1.85, 95% CI 1.17-2.92; p < 0.009) and postchemotherapy (10.3 vs 16.3 mo; HR 2.43, 95% CI 1.24-4.76; p < 0.008) cohorts. The frequency of a 25% PSA rise at 4 wk was similar in the prechemotherapy and postchemotherapy populations, possibly reflecting the 30% of patients with AA-refractory disease regardless of --PSA = prostate-specific antigen; CI = confidence interval, NPV = negative predictive value, PPV = positive predictive value. a To estimate the PPV and NPV of a 30% PSA response, the prevalence was estimated using the rates of 30% PSA response at 12 wk for the COU-301
(postchemotherapy cohort) and COU-302 (prechemotherapy cohort) trials, respectively. 
prior docetaxel therapy. The data also indicate that a PSA response is very uncommon after a 25% PSA rise at 4 wk. A previous retrospective study reported an 8.7% (9/103) flare rate on AA as second-line treatment [20] . Our data may differ because of our more stringent definition of flare, in accordance with PCWG criteria. Finally, this study is limited by its retrospective nature and requires further validation in prospective studies. Moreover, it involved outcomes for patients at a single institution, so confirmation, preferably in multicentre international studies, is required.
Conclusion
PSA changes as early as 4 wk after AA initiation are highly associated with OS and PSA response at 12 wk in both prechemotherapy and postchemotherapy (docetaxel) settings. PSA flare is uncommon following AA. Prospective trials are now warranted to further validate these findings to give clinicians robust data that can assist them with earlier decisions to switch treatment.
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